Dermatologic Manifestations of Verrucous Carcinoma Treatment & Management
- Author: Bassam Zeina, MD, PhD; Chief Editor: William D James, MD more...
Surgical Care
Most physicians treat patients with cutaneous verrucous carcinoma (VC) in their offices. Complete tumor extirpation should be performed at first presentation because verrucous carcinoma can recur, metastasize, and, ultimately, cause death. Recurrent verrucous carcinoma carries a relatively poor prognosis.
Surgical excision and Mohs micrographic (MMS) surgery represent the treatments of choice for cutaneous verrucous carcinomas.[31]
Excision with conventional margins [32]
Simple excision is most valuable in the treatment of small verrucous carcinomas of the trunk and extremities and in areas in which tissue sparing is not essential.
Cure rates following simple excision of well-defined T1 lesions can be as high as 95-99%.
A 4-mm margin of healthy tissue is recommended for straightforward lesions.
Standard excision with permanent conventional sections is a highly effective treatment for many verrucous carcinomas. The depth of the excision should include the subcutaneous fat because even small verrucous carcinomas may extend into the subcutaneous fat.
The disadvantages of excision with an arbitrary margin are that in some cases, the pathology reveals a subclinical positive margin, requiring further surgery. In extensive tumors with inflammatory changes, the surgical margin may be difficult to define. Additionally, more healthy tissue may be excised than is necessary.[8]
Mohs surgery [33, 34, 35]
A dermatologic surgeon usually offers MMS. The main advantage of MMS over simple excision in the extirpation of cutaneous verrucous carcinoma is the ability to examine all excision margins (deep and lateral) and to carefully map residual foci of invasive carcinoma.
MMS provides a cure rate for verrucous carcinoma of 94-100% and has been of particular value in curing verrucous carcinoma with perineural invasion. MMS offers the added benefit of preserving normal tissue, thus facilitating reconstruction.
MMS is performed routinely in an outpatient setting with the patient under local anesthesia.
MMS is not widely available outside the United States.
A multidisciplinary approach using MMS performed in conjunction with a plastic surgeon, otolaryngologist, and radiation oncologist may allow for the complete removal of deeply invasive verrucous carcinoma, preservation of vital structures, and facilitation of the reconstruction of a large operative defect.
Because of its many advantages, MMS is the procedure of choice for verrucous carcinoma for which tissue preservation is needed. Furthermore, surgery for verrucous carcinoma using MMS may be an integral component in the management of certain verrucous carcinomas that otherwise would be beyond the experience of the cutaneous surgeon.
Cryosurgery [36]
Cryosurgery using liquid nitrogen is a safe and low-cost procedure for the ablation of selected verrucous carcinomas and is well tolerated by patients.
Cryotherapy has provided a high cure rate for select well-circumscribed superficial verrucous carcinomas. Because of no histologic control, close follow-up is necessary.
This procedure is the least likely to result in cure and is the least preferred intervention.
Curettage and electrodesiccation
Cure rates of 96-99% have been quoted in several large studies for destruction of T0 and T1 verrucous carcinoma (ie, in situ lesions and invasive lesions < 2 cm in diameter). This high cure rate was affected by careful patient selection.
The main disadvantage of curettage and electrodesiccation is a lack of margin control; nonetheless, the procedure is minimally invasive, well tolerated, and effective for in situ lesions without deep involvement.
Curettage and electrodesiccation is most appropriate for slow-growing lesions of the trunk and extremities.
Radiation therapy [37, 38, 39]
Radiation therapy offers the potential advantage of avoiding the trauma and deformity of a surgical procedure, but it has occasionally been associated with transformation to high-grade squamous carcinoma.
Ionizing radiation therapy is used mainly as a treatment for primary cutaneous carcinoma in patients who cannot tolerate surgery (eg, elderly patients).
Cure rates for T1 lesions range from 85-95%.
Although the initial cosmetic result following radiation often is good, the long-term result frequently is poor, with atrophy, hypopigmentation, and telangiectasia. Some patients treated with radiation also develop radiation necrosis. This risk increases over time.
Radiation therapy is not advocated for use over bony structures because of the risk of osteoradionecrosis. Radiation therapy is not advocated for patients who are young or of middle aged.
Radiation therapy is expensive and requires multiple visits. The procedure is blind to histologic margin control. For these reasons, the use of radiation as primary therapy for verrucous carcinoma generally is restricted to older patients who cannot tolerate or who refuse surgery.
Other considerations
Other treatments that have been used for cutaneous verrucous carcinomas with variable success include topical or systemic chemotherapy (bleomycin, 5-fluorouracil, cisplatin, methotrexate), carbon-dioxide laser, intralesional interferon alfa, imiquimod, and photodynamic therapy.[40]
In oral verrucous carcinoma in the presence of clinical lymphadenopathy and if the pathological diagnosis is uncertain, neck treatment should be considered.[8]
If bone involvement is suspected, radiography or computed tomography scanning should be performed.
Ackerman LV. Verrucous carcinoma of the oral cavity. Surgery. Apr 1948;23(4):670-8. [Medline].
Aird I, Johnson HD, Lennox B, Stansfeld AG. Epithelioma cuniculatum: a variety of squamous carcinoma peculiar to the foot. Br J Surg. Nov 1954;42(173):245-50. [Medline].
Aroni K, Lazaris AC, Ioakim-Liossi A, Paraskevakou H, Davaris PS. Histological diagnosis of cutaneous "warty" carcinoma on a pre-existing HPV lesion. Acta Derm Venereol. Jul-Aug 2000;80(4):294-6. [Medline].
Mirbod SM, Ahing SI. Tobacco-associated lesions of the oral cavity: Part II. Malignant lesions. J Can Dent Assoc. Jun 2000;66(6):308-11. [Medline].
Terada T. Verrucous carcinoma of the skin: a report on 5 Japanese cases. Ann Diagn Pathol. Jun 2011;15(3):175-80. [Medline].
Hagiwara H, Kanazawa T, Ishikawa K, et al. Invasive verrucous carcinoma: a temporal bone histopathology report. Auris Nasus Larynx. Apr 2000;27(2):179-83. [Medline].
Grinspan D, Abulafia J. Oral florid papillomatosis (verrucous carcinoma). Int J Dermatol. Oct 1979;18(8):608-22. [Medline].
Walvekar RR, Chaukar DA, Deshpande MS, et al. Verrucous carcinoma of the oral cavity: A clinical and pathological study of 101 cases. Oral Oncol. Jan 2009;45(1):47-51. [Medline].
Depprich RA, Handschel JG, Fritzemeier CU, Engers R, Kubler NR. Hybrid verrucous carcinoma of the oral cavity: A challenge for the clinician and the pathologist. Oral Oncology EXTRA. 2006;42:85-90.
Castano E, Lopez-Rios F, Alvarez-Fernandez JG, Rodriguez-Peralto JL, Iglesias L. Verrucous carcinoma in association with hypertrophic lichen planus. Clin Exp Dermatol. Jan 1997;22(1):23-5. [Medline].
Warshaw EM, Templeton SF, Washington CV. Verrucous carcinoma occurring in a lesion of oral lichen planus. Cutis. Apr 2000;65(4):219-22. [Medline].
Levy A, Lebbe C. [Buschke-Löwenstein tumour: diagnosis and treatment]. Ann Urol (Paris). Jun 2006;40(3):175-8. [Medline].
Blackmore CC, Ratcliffe NR, Harris RD. Verrucous carcinoma of the bladder. Abdom Imaging. Sep-Oct 1995;20(5):480-2. [Medline].
Groeneveld AE. Verrucous carcinoma of the bladder. Br J Urol. Jul 1992;70(1):96-7. [Medline].
D'Aniello C, Grimaldi L, Meschino N, Brandi C, Andreassi A, Bosi B. Verrucous 'cuniculatum' carcinoma of the sacral region. Br J Dermatol. Aug 2000;143(2):459-60. [Medline].
Gallo A, Fiorella ML, Simonelli M, Rocca CD, de Vincentiis M. Carcinoma cuniculatum: verrucous carcinoma of the skin of the face. Otolaryngol Head Neck Surg. Oct 2005;133(4):640. [Medline].
Ho J, Diven DG, Butler PJ, Tyring SK. An ulcerating verrucous plaque on the foot. Verrucous carcinoma (epithelioma cuniculatum). Arch Dermatol. Apr 2000;136(4):547-8, 550-1. [Medline].
Kao GF, Graham JH, Helwig EB. Carcinoma cuniculatum (verrucous carcinoma of the skin): a clinicopathologic study of 46 cases with ultrastructural observations. Cancer. Jun 1 1982;49(11):2395-403. [Medline].
Kempe SA, Kreiser DZ. Epithelioma cuniculatum of the foot. Literature survey and case history. J Am Podiatry Assoc. Jul 1984;74(7):351-4. [Medline].
Pattee SF, Bordeaux J, Mahalingam M, Nitzan YB, Maloney ME. Verrucous carcinoma of the scalp. J Am Acad Dermatol. Mar 2007;56(3):506-7. [Medline].
Kuan YZ, Hsu HC, Kuo TT, Huang YH, Ho HC. Multiple verrucous carcinomas treated with acitretin. J Am Acad Dermatol. Feb 2007;56(2 Suppl):S29-32. [Medline].
Vandeweyer E, Sales F, Deraemaecker R. Cutaneous verrucous carcinoma. Br J Plast Surg. Mar 2001;54(2):168-70. [Medline].
Huang SH, Lockwood G, Irish J, et al. Truths and myths about radiotherapy for verrucous carcinoma of larynx. Int J Radiat Oncol Biol Phys. Mar 15 2009;73(4):1110-5. [Medline].
Witt RL, Wilson P. Missed opportunity for larynx preservation? Failure to distinguish verrucous and squamous cell carcinoma on microlaryngoscopy and biopsy. J Voice. Jan 2009;23(1):140-2. [Medline].
Shidara Y, Karube A, Watanabe M, et al. A case report: verrucous carcinoma of the endometrium--the difficulty of diagnosis, and a review of the literature. J Obstet Gynaecol Res. Jun 2000;26(3):189-92. [Medline].
Shiomori T, Udaka T, Nagatani G, et al. Association of verrucous carcinoma and inverted papilloma in the sinonasal tract. Auris Nasus Larynx. Jun 2007;34(2):281-5. [Medline].
Cosman BC, O'Grady TC, Pekarske S. Verrucous carcinoma arising in hidradenitis suppurativa. Int J Colorectal Dis. Nov 2000;15(5-6):342-6. [Medline].
Nasca MR, Innocenzi D, Micali G. Penile cancer among patients with genital lichen sclerosus. J Am Acad Dermatol. Dec 1999;41(6):911-4. [Medline].
Masih AS, Stoler MH, Farrow GM, Wooldridge TN, Johansson SL. Penile verrucous carcinoma: a clinicopathologic, human papillomavirus typing and flow cytometric analysis. Mod Pathol. Jan 1992;5(1):48-55. [Medline].
Miyamoto T, Sasaoka R, Hagari Y, Mihara M. Association of cutaneous verrucous carcinoma with human papillomavirus type 16. Br J Dermatol. Jan 1999;140(1):168-9. [Medline].
Abbas MA. Wide local excision for Buschke-Löwenstein tumor or circumferential carcinoma in situ. Tech Coloproctol. Sep 2011;15(3):313-8. [Medline].
Yeh CJ. Treatment of verrucous hyperplasia and verrucous carcinoma by shave excision and simple cryosurgery. Int J Oral Maxillofac Surg. Jun 2003;32(3):280-3. [Medline].
Alkalay R, Alcalay J, Shiri J. Plantar verrucous carcinoma treated with Mohs micrographic surgery: a case report and literature review. J Drugs Dermatol. Jan 2006;5(1):68-73. [Medline].
Muro Vidaurre I, Hernaez Manrique I, Sanz Jaka JP, Rekarte Barriola JA, Lluch Costa A. [Verrucous carcinoma of the penis: local excision with the Mohs micrographic technique]. Arch Esp Urol. Nov 1996;49(9):959-64. [Medline].
Padilla RS, Bailin PL, Howard WR, Dinner MI. Verrucous carcinoma of the skin and its management by Mohs' surgery. Plast Reconstr Surg. Mar 1984;73(3):442-7. [Medline].
Ishida CE, Ramos-e-Silva M. Cryosurgery in oral lesions. Int J Dermatol. Apr 1998;37(4):283-5. [Medline].
Ferlito A, Rinaldo A, Mannara GM. Is primary radiotherapy an appropriate option for the treatment of verrucous carcinoma of the head and neck?. J Laryngol Otol. Feb 1998;112(2):132-9. [Medline].
Foroudi F, Turner S. Verrucous scrotal carcinoma: a radioresponsive tumor. J Urol. Nov 1999;162(5):1694-5. [Medline].
Schwade JG, Wara WM, Dedo HH, Phillips TL. Radiotherapy for verrucous carcinoma. Radiology. Sep 1976;120(3):677-9. [Medline].
Nikkels AF, Thirion L, Quatresooz P, Piérard GE. Photodynamic therapy for cutaneous verrucous carcinoma. J Am Acad Dermatol. Sep 2007;57(3):516-9. [Medline].

